Howard Mayer - 07 Jul 2022 Form 4 Insider Report for Entasis Therapeutics Holdings Inc.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
11 Jul 2022, 16:06:51 UTC
Prior SEC filing
24 Jun 2022
Next SEC filing
14 Nov 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Elizabeth M. Keiley as Attorney-in-Fact for Howard Mayer

Key filing fact

Howard Mayer filed Form 4 for Entasis Therapeutics Holdings Inc. on 11 Jul 2022.

Key facts

  • This page summarizes Howard Mayer's Form 4 filing for Entasis Therapeutics Holdings Inc..
  • 4 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 11 Jul 2022, 16:06.

Change

  • Previous filing in this sequence was filed on 24 Jun 2022.
  • Current net transaction value: -$108,900.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ETTX transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
$48,400
Shares
-22,000
Change %
-100%
Price
$2.20
Shares after
0
Date
07 Jul 2022
Ownership
Direct
Footnotes
F1
ETTX transaction

Common Stock

Disposed to Issuer

Transaction value
$60,500
Shares
-27,500
Change %
-100%
Price
$2.20
Shares after
0
Date
11 Jul 2022
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ETTX transaction Derivative

Stock Option (right to buy)

Other

Transaction value
$0
Shares
-12,500
Change %
-100%
Price
$0.000000*
Shares after
0
Date
11 Jul 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
12,500
Exercise price
$2.44
Footnotes
F3
ETTX transaction Derivative

Stock Option (right to buy)

Other

Transaction value
$0
Shares
-11,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
11 Jul 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
11,000
Exercise price
$2.98
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Howard Mayer is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price").

Footnote F2

Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20.

Footnote F3

Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .